← Eichor
Condition: Anti Phospholipid Syndrome Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Anti Phospholipid Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)
Phase 2 · 1 location(s) · National and Kapodistrian University of Athens · NCT07584083Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1 · 77 location(s) · Chugai Pharmaceutical · NCT06371417Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06828042Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
NA · 1 location(s) · Centre Hospitalier Universitaire, Amiens · NCT06373926A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NA · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06379646Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270Rheumatology Patient Registry and Biorepository
Phase N/A · 1 location(s) · Yale University · NCT04402086Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
Phase N/A · 3 location(s) · McMaster University · NCT05646394International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
Phase N/A · 1 location(s) · Stéphane Zuily · NCT04262492Daratumumab in Primary Antiphospholipid Syndrome
Phase 1/Phase 2 · 8 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT05671757Negative Antiphospholipid Syndrome: a Multicentric Study
Phase N/A · 1 location(s) · Italian Society for Rheumatology · NCT06373003Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Phase 1 · 2 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236801Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT05786235Anti-CD38 Antibody Treating APS With Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05983952Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
Phase N/A · 1 location(s) · University of California, Davis · NCT00616317Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
Phase N/A · 18 location(s) · Peking Union Medical College Hospital · NCT05230017New Biological Tests in Patients With Antiphospholipid Antibodies
Phase N/A · 4 location(s) · Hospices Civils de Lyon · NCT03890601Laboratory and Clinical Data in Antiphospholipid Patients
Phase N/A · 2 location(s) · Central Hospital, Nancy, France · NCT04308564Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic AP
Phase N/A · 2 location(s) · Infanta Leonor University Hospital · NCT07372170Follow-up Cohort of Patients With Antiphospholipid Syndrome
Phase N/A · 1 location(s) · University Hospital, Rouen · NCT07178925Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Phase 4 · 2 location(s) · University of Sao Paulo General Hospital · NCT07087912Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Phase N/A · 6 location(s) · Santé Arménie French-Armenian Research Center · NCT05904301A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07123519Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Phase 2 · 2 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05199909An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236762Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholip
Phase 4 · 32 location(s) · Seoul National University Hospital · NCT05995600IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Phase 2 · 3 location(s) · David Ware Branch · NCT03152058Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)
NA · 1 location(s) · CHU de Reims · NCT07163338
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.